Analysis of the clinical application of seliniso (Silvio) in the treatment of acute leukemia

Selinexor (Selinexor) is a new type of oral selective inhibitor of Nuclear Export (SINE). Its mechanism of action is mainly by inhibiting the nuclear export protein XPO1, leaving tumor suppressor proteins and key factors that regulate apoptosis in the nucleus, thereby inducing apoptosis of cancer cells and inhibiting their proliferation. In the treatment of acute leukemia (Acute Leukemia, AL), selinesol, with its unique mechanism of action, provides a new treatment option for patients with refractory or relapsed acute leukemia.

Clinical trial data show that selinesol combined with other chemotherapy drugs, such as low-dose cytarabine or decitabine, can produce considerable remission rates in patients with relapsed and refractory acute myeloid leukemia (AML). Some studies have shown that combined drug regimens can improve the complete response rate (CR) and disease-free survival time (DFS), while prolonging overall survival (OS) in some high-risk patients. Compared with traditional chemotherapy, selinexol's oral administration method is simple and provides patients with a more flexible treatment path.

During clinical application, the safety and tolerability of selinesol are also important considerations. Common adverse reactions include bone marrow suppression (such as neutropenia, thrombocytopenia), gastrointestinal reactions (nausea, vomiting, decreased appetite), fatigue and hypotension. In order to ensure the safety of treatment, patients need to regularly monitor blood routine, electrolytes, liver and kidney function during medication, and provide supportive treatment when necessary, such as using growth factors, antiemetics, or adjusting medication dosage.

Overall, selinesol has shown good anti-tumor activity in the treatment of acute leukemia, especially providing a new treatment option for relapsed or refractory patient groups. Through reasonable combination drug strategies, individualized dosage adjustments and strict safety monitoring, the efficacy can be maximized, adverse reactions can be reduced, and more potential clinical intervention options can be provided for patients with acute leukemia.

Reference link:https://www.drugs.com